4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Announces New Employment Inducement Grants

15 8 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

11 8 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

06 8 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

31 7 2025 13:05:01 提供 Nasdaq GlobeNewswire

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

24 7 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

11 7 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

02 7 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

28 5 2025 05:00:31 提供 Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

16 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

08 5 2025 13:05:03 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

05 5 2025 05:00:21 提供 Nasdaq GlobeNewswire

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

01 5 2025 05:00:46 提供 Nasdaq GlobeNewswire

4DMT Announces New Employment Inducement Grants

11 4 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

27 3 2025 05:00:10 提供 Nasdaq GlobeNewswire

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

10 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

28 2 2025 13:05:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

19 2 2025 05:00:36 提供 Nasdaq GlobeNewswire

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

08 2 2025 11:30:24 提供 Nasdaq GlobeNewswire

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

29 1 2025 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

10 1 2025 05:00:00 提供 Nasdaq GlobeNewswire